The startup has developed a home-based medical diagnostic screening device that enables self-administered tests for prevalent diseases, including lung, liver, and kidney conditions. This device provides immediate health monitoring and affordable imaging indicators, facilitating early diagnosis and treatment without the need for hospital visits.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current clinical methods for screening prevalent diseases affecting organs like the lungs, liver, and kidneys often require hospital visits and specialized equipment, creating barriers to early detection and preventative care. This can lead to delayed diagnoses and increased healthcare costs associated with managing advanced-stage conditions.
Solution
Gense Technologies offers mediscan, a portable AI health screening device that enables convenient and non-invasive monitoring of organ-specific health indexes for the liver, lungs, and kidneys. The device utilizes electrical impedance tomography (EIT) to scan the body and estimate clinical standard tests, with results displayed in real-time via a user-friendly mobile application. By facilitating health screenings in various settings, including clinics, community centers, homes, and corporate wellness programs, mediscan aims to shift healthcare towards a prevention-focused, community-based system. The device adheres to international safety and quality standards for medical devices and is manufactured in accordance with ISO 13485 certified quality standards.
Target Audience
The primary target audience includes individuals seeking preventative health screenings, corporate wellness programs, clinics, elderly care services, and healthcare providers aiming to improve accessibility and early detection of prevalent diseases.
Features
- Portable device with a belt and mobile app for organ-specific health monitoring.
- Non-invasive electrical impedance tomography (EIT) technology for scanning organs.
- Real-time health reports generated within minutes, estimating clinical standard tests.
- Screening capabilities for prevalent diseases affecting the liver (e.g., MASLD), lungs (e.g., COPD, asthma), and kidneys (e.g., CKD).
- Mobile app provides simple breathing instructions and displays disease risk assessment.
- Adherence to IEC 60601 safety compliance and ISO 13485 certified manufacturing.
- Commercially sold under HKMHDIA Certificate of Free Sales.
- Validated results through randomized clinical trials at Queen Mary Hospital with University of Hong Kong professors.